Evidence map›Paper›PMID 39278987›Full record

SynthesisPediatric nephrology (Berlin, Germany)2025

Etiology, clinical profile, and outcomes of crescentic glomerulonephritis in children: a systematic review.

Jitendra Meena, Parnika Nangla, Sanjay Ojha, Aditi Sinha, Pankaj Hari, Arvind Bagga

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Pediatric nephrology (Berlin, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Eculizumab for rapidly progressive glomerulonephritis in children.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026
    Article
  3. Article
  4. Anti-glomerular basement membrane disease-treatment standard.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025
    Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jitendra MeenaDivision of Nephrology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.
Parnika NanglaDivision of Nephrology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.
Sanjay OjhaDivision of Nephrology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.
Aditi SinhaDivision of Nephrology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.
Pankaj HariDivision of Nephrology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.
Arvind BaggaDivision of Nephrology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India. arvindbagga@hotmail.com.ORCID http://orcid.org/0000-0002-7832-684X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCrescentic glomerulonephritis, if not managed promptly, is associated with unsatisfactory outcomes. There are limited studies reporting the outcomes of crescentic glomerulonephritis in children.

objectivesThis systematic review is aimed at synthesizing the data on etiology, clinical profile, and outcomes of crescentic glomerulonephritis in children. DATA SOURCES: We performed a literature search using PubMed, Embase, and Web of Science from inception to January 2024 without language or geographic restrictions. STUDY ELIGIBILITY CRITERIA: Cohort and cross-sectional studies with at least 10 participants reporting etiology, clinical features, and outcomes on crescentic glomerulonephritis in children were considered eligible. PARTICIPANTS AND

interventionsChildren aged less than 18 years with crescentic glomerulonephritis. STUDY APPRAISAL AND SYNTHESIS

methodsWe used a tool by Hoy et al. for assessing the quality of studies. We calculated pooled estimates using random effect meta-analyses. Primary outcome was the pooled proportion of patients progressing to kidney failure.

resultsFrom 1706 records, we included 36 studies (1548 participants) from 16 countries. Etiology was immune-complex glomerulonephritis in 76% (95% CI 67 to 85), pauci-immune in 19% (13 to 25), and anti-GBM disease in 5% (3 to 7) of patients. Gross hematuria, oliguria, edema, and hypertension were observed in 63% (41 to 82), 57% (34 to 79), 79% (65 to 90), and 64% (49 to 77), respectively. In-hospital mortality, reported in 11 studies, was 7% (4 to 11). Progression to kidney failure and chronic kidney disease was reported in 27% (21 to 33) and 50% (29 to 71) of patients, respectively. Risk factors for kidney failure included oliguria, dialysis requirement at onset, estimated GFR, proportion of fibrous crescents, and pauci-immune glomerulonephritis as the underlying etiology. LIMITATIONS: High heterogeneity in pooled estimates of the outcomes. CONCLUSIONS AND IMPLICATIONS OF KEY

findingsImmune-complex glomerulonephritis is the most common etiology in children, with edema, hypertension, gross hematuria, and oliguria being the chief presenting manifestations. Almost one in every four patients with crescentic glomerulonephritis progressed to kidney failure. SYSTEMATIC REVIEW REGISTRATION NUMBER: PROSPERO registration number CRD42024500515.

Indexed as

GlomerulonephritisAdolescentChildChild, PreschoolDisease ProgressionHumansChronic kidney diseaseCrescentsKidney failureRapidly progressive glomerulonephritis

Identifiers

PMID39278987

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.